Checkmate Pharmaceuticals, Inc. (CMPI), relating to its proposed acquisition by Regeneron Pharmaceuticals, Inc. Under the terms of the tender offer, CMPI shareholders are expected to receive $10.50 in cash per share they own.
Checkmate Pharmaceuticals, Inc. (CMPI), relating to its proposed acquisition by Regeneron Pharmaceuticals, Inc. Under the terms of the tender offer, CMPI shareholders are expected to receive $10.50 in cash per share they own.